Hematopoiesis News Volume 5.14 | Apr 15 2014

Mouse SLX4 Is a Tumor Suppressor that Stimulates the Activity of the Nuclease XPF-ERCC1 in DNA Crosslink Repair
Investigators uncovered consequences of mouse Slx4 deficiency and reveal its function in DNA crosslink repair. Slx4-deficient mice develop epithelial cancers and have a contracted hematopoietic stem cell pool. [Mol Cell] Full Article | Graphical Abstract

TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells
Scientists showed that Ten-Eleven-Translocation 2 (TET2) expression is low in human embryonic stem (ES) cell lines and increases during hematopoietic differentiation. ShRNA-mediated TET2 knockdown had no effect on the pluripotency of various ES cells. [Stem Cells] Abstract

Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133⁺ Tumor-Initiating Cells
Researchers demonstrated that a subset of primary mantle cell lymphoma (MCL) cells co-cultured with either primary human mesenchymal stromal cells or murine MS-5 cells form in cobblestone-areas consisting of cells with a primitive immunophenotype containing the chromosomal translocation t (11;14)(q13;q32) characteristic of MCL. [PLoS One] Full Article

Arsenite Selectively Inhibits Mouse Bone Marrow Lymphoid Progenitor Cell Development In Vivo and In Vitro and Suppresses Humoral Immunity In Vivo
In the bone marrow, As⁺³ altered neither the expression of CD34+ and CD38+ cells, markers of early hematopoietic stem cells, nor CD45-/CD105+, markers of mesenchymal stem cells. [PLoS One] Full Article

CLINICAL RESEARCH

A Phase I Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers
ACE-536 acts through a mechanism distinct from erythropoiesis-stimulating agents to promote late-stage erythroid differentiation by binding to TGF-β superfamily ligands and inhibiting signaling through transcription factors Smad 2/3. The goal of this Phase I study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ascending dose levels of ACE-536 in healthy volunteers. [Am J Hematol] Abstract

Outcomes of Lung Transplantation after Allogeneic Hematopoietic Stem Cell Transplantation
Researchers describe the indications and outcomes in patients who had lung transplantation after HCT for hematologic disease from a retrospective case series at our institution and a review of the medical literature. [Biol Blood Marrow Transplant] Abstract

Impact of Cotransplantation of Mesenchymal Stem Cells on Lung Function after Unrelated Allogeneic Hematopoietic Stem Cell Transplantation following Non-Myeloablative Conditioning
Investigators prospectively followed 30 patients who underwent unrelated hematopoietic stem cell transplantation (HSCT) with mesenchymal stem cell co-infusion after non-myeloablative conditioning. Each patient underwent detailed lung function testing and measurement of exhaled nitric oxide before HSCT and 3, 6, and 12 months posttransplant. [Transplantation] Abstract

A Double-Blind, Randomized, Controlled Trial on N-Acetylcysteine for the Prevention of Acute Kidney Injury in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Investigators evaluated the effects of intravenous N-acetylcysteine on the prevention of acute kidney injury in allogeneic hematopoietic stem cell transplantation patients. [Hematol Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid Leukemia Treatment
BioLineRx announced that Prof. Arnon Nagler has received final regulatory approval to evaluate BioLineRx’s BL-8040 as a treatment for chronic myeloid leukemia in a Phase I/II clinical study. [BioLineRx] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis research community.

Postdoctoral Researcher – Regulation of Lymphoid Development (Lund University)

MSc & PhD Positions – Cell Biology, Neurobiology, Neuroimmunology, Cancer Biology, Computational Biology (Hanyang University)

Research Associate – Hematology/Oncology (University of Chicago)

Postdoctoral Fellow – Hematopoietic Stem Cell and Leukemia Research (City of Hope)

Postdoctoral Position – Immunotherapies for Cancer Based on Genetic Engineered T Lymphocytes and/or Hematopoietic Stem Cells (Roswell Park Cancer Institute)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (The Icahn School of Medicine at Mount Sinai)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Human Stem Cell Biology and Hematopoiesis (Johns Hopkins University School of Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.